Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
100 results
  • Leukemia

20-191          Phase I

A Phase 1 Study of PF-08046040/SEA-CD70 in Myeloid Malignancies

  • Pancreatic Cancer, Esophageal Cancer, Gastric (Stomach) Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Lymphoma

23-330          Phase I

A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

  • Prostate Cancer

25-336          Phase I

A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)

  • Cellular Therapy

2024P001014          Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

  • Bladder Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Breast Cancer

24-707          Phase I

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Ovarian Cancer

24-472          Phase I

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

  • Leukemia

24-172          Phase I

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

Showing 1 - 10 of 100 results